DeutschNewstral
Article
bizjournals.com on 2021-07-19 18:06
Gene therapy developer Passage Bio adds a trio to its C-suite
Related news
- Passage Bio further expands gene therapy research partnership with Pennbizjournals.com
- Gene therapy developer bluebird bio to cut 30% of staffbizjournals.com
- Philadelphia gene therapy firm Passage Bio signs lease deal for lab space in New Jerseybizjournals.com
- Gene therapy startup Passage Bio raises $110M Series B, its second raise in less than a yearbizjournals.com
- Gene therapy developer Gyroscope Technologies raises $60.6Mbizjournals.com
Gene Therapy: A fly on the Super Suite wallpost-gazette.com- FBluebird Bio prices gene therapy at nearly $1.8mft.com
- BIO 2019: Gene therapy surging, but challenges remainbizjournals.com
- Cambridge gene therapy firm bluebird bio to move to Somervillebizjournals.com
- Gene therapy firm bluebird bio to split into two companiesbizjournals.com
- BBluebird Bio Suspends Gene Therapy Trials, Marketing After Cancer Diagnosisbarrons.com
- Spark Therapeutics sues gene therapy rival Bluebird Biobizjournals.com
- Bluebird bio sued by gene therapy rival Spark Therapeuticsbizjournals.com
- Malvern gene therapy developer to acquire publicly traded Boston companybizjournals.com
- Philadelphia gene therapy developer, backed by $250M, makes first acquisitionbizjournals.com
- Chester County gene therapy developer closes $41.9M funding roundbizjournals.com
- Gene therapy firm expanding in RTP bulks up C-suite with industry veteranbizjournals.com
- Passage Bio secures FDA fast track status for three 'potentially transformative' gene therapiesbizjournals.com
- Gene therapy firm Bluebird Bio, with Durham site, to split into two companiesbizjournals.com
- News out of bluebird bio could delay IPOs for two local gene therapy firmsbizjournals.com